Educational series provides strategies for maintaining optimal therapy with anti-VEGF injections
In a 4-part educational series, Dr Jeffrey Heier and Dr Charles Wykoff, along with patient advocate Matthew Levine, will provide strategies for adapting eye care and anti-VEGF injections to fit the evolving COVID-19 environment.
The program, Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapies: Updates in Diabetic Eye Diseases, Retinal Vein Occlusion and Age-Related Macular Degeneration – A Four-Part Series, is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with The American Macular Degeneration Foundation and will be available starting November 17.
Module 1, “Anti-VEGF Injections in the Era of COVID-19: Implications for Patients,” will discuss the provision of care during the pandemic and share strategies to reduce the risk of transmission between patients, clinicians, and staff.
During Module 2, “Management of the Diabetic Retinopathy: What is New?,” the expert panelists will review the most recent data from studies lead by DRCR Retina Network with anti-VEGF therapies and the impacts on management and best practices in the care of DR and DME.
Module 3, “Evolution of the Treatment Paradigm for AMD: Evaluating the Data from Clinical and Real-life Experience,” will look at progress with the use of modified dosing regimens and new agents to maximizing visual outcomes in AMD.
Finally, Module 4, “Treatment Choices for Retinal Vein Occlusion (RVO),” will explore the latest guidance on selecting and ordering treatments for RVOs.
Full CME information can be found here.
